All Stories

  1. Biosimilars of low-molecular-weight heparin products: fostering competition or reducing ‘biodiversity’?

    Article • Journal of Thrombosis and Haemostasis, January 2016, Wiley

    Job Harenberg

  2. Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2016, De Gruyter

    Job Harenberg

  3. Chromogenic assays for measurement of rivaroxaban from EDTA anticoagulated plasma samples

    Article • Thrombosis and Haemostasis, September 2015, Schattauer GmbH

    Job Harenberg

  4. Residual vein thrombosis and the risk of subsequent serious complications

    Article • Thrombosis Research, July 2015, Elsevier

    Job Harenberg

  5. Measurement of Non–Vitamin K Antagonist Oral Anticoagulants in Patient Plasma Using Heptest-STAT Coagulation Method

    Article • Therapeutic Drug Monitoring, June 2015, Wolters Kluwer Health

    Job Harenberg

  6. Pharmacokinetics of Certoparin During In Vitro and In Vivo Dialysis

    Article • Artificial Organs, April 2015, Wiley

    Job Harenberg

  7. Development of Recommendations to Continue Anticoagulation with One of the Two Types of Oral Anticoagulants Based on the Identification of Patients' Preference

    Article • Seminars in Thrombosis and Hemostasis, February 2015, Thieme Publishing Group

    Job Harenberg

  8. Next Generation Antithrombotic Therapy: Focus on Antisense Therapy against Coagulation Factor XI

    Article • Seminars in Thrombosis and Hemostasis, February 2015, Thieme Publishing Group

    Job Harenberg

  9. Arterial and Venous Thrombosis following Trauma and Major Orthopedic Surgery: Molecular Mechanisms and Strategies for Intervention

    Article • Seminars in Thrombosis and Hemostasis, February 2015, Thieme Publishing Group

    Job Harenberg

  10. Patients' Serum and Urine as Easily Accessible Samples for the Measurement of Non–Vitamin K Antagonist Oral Anticoagulants

    Article • Seminars in Thrombosis and Hemostasis, February 2015, Thieme Publishing Group

    Job Harenberg

  11. The Impact of Residual Thrombosis on the Long-Term Outcome of Patients with Deep Venous Thrombosis Treated with Conventional Anticoagulation

    Article • Seminars in Thrombosis and Hemostasis, February 2015, Thieme Publishing Group

    Dr Raffaele Pesavento, Job Harenberg

  12. Determination of dabigatran in plasma, serum, and urine samples: comparison of six methods

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2015, De Gruyter

    Job Harenberg

  13. Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany

    Article • BioMed Research International, January 2015, Hindawi Publishing Corporation

    Job Harenberg

  14. Treatment of deep vein thrombosis in patients with pulmonary embolism

    Article • Blood Coagulation & Fibrinolysis, December 2014, Wolters Kluwer Health

    Job Harenberg

  15. Entwicklung eines Fragebogens zur Identifikation der Präferenz von Patienten für ein konventionelles oder ein direktes orales Antikoagulanz

    Article • MMW - Fortschritte der Medizin, December 2014, Springer Science + Business Media

    Job Harenberg

  16. Anticoagulation in patients with impaired renal function and with haemodialysis

    Article • November 2014, Schattauer GmbH

    Job Harenberg

  17. Glycosaminoglycans: Anticoagulant and Nonanticoagulant Actions: A Short History of Symposia Held at Villa Vigoni

    Article • Seminars in Thrombosis and Hemostasis, November 2014, Thieme Publishing Group

    Job Harenberg

  18. Determination of Rivaroxaban and Apixaban in plasma and serum

    Article • European Journal of Clinical Investigation, July 2014, Wiley

    Job Harenberg

  19. Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH

    Article • Journal of Thrombosis and Haemostasis, May 2014, Elsevier

    Job Harenberg

  20. Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries: The RE-LY Atrial Fibrillation Registry

    Article • Circulation, January 2014, Wolters Kluwer Health

    Job Harenberg

  21. Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2014, De Gruyter

    Job Harenberg

  22. Development of a Tool to Identify Patients' Preference for Vitamin K Antagonist or Direct Oral Anticoagulant Therapy

    Article • Seminars in Thrombosis and Hemostasis, December 2013, Thieme Publishing Group

    Job Harenberg

  23. Determination of Direct Oral Anticoagulants from Human Serum Samples

    Article • Seminars in Thrombosis and Hemostasis, December 2013, Thieme Publishing Group

    Job Harenberg

  24. Compositional Differences in Commercially Available Prothrombin Complex Concentrates

    Article • Clinical and Applied Thrombosis/Hemostasis, November 2013, SAGE Publications

    Job Harenberg

  25. Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries

    Article • Journal of Thrombosis and Thrombolysis, September 2013, Springer Science + Business Media

    Job Harenberg

  26. Oral Apixaban for the Treatment of Acute Venous Thromboembolism

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, August 2013, New England Journal of Medicine (NEJM/MMS)

    Job Harenberg

  27. Update of the recommendations on biosimilar low-molecular-weight heparins from the Scientific Subcommittee on Control of Anticoagulation of the International Society on Thrombosis and Haemostasis

    Article • July 2013, Wiley

    Job Harenberg

  28. Quantifying the Effect of Covariates on Concentrations and Effects of Steady-State Phenprocoumon Using a Population Pharmacokinetic/Pharmacodynamic Model

    Article • Clinical Pharmacokinetics, March 2013, Springer Science + Business Media

    Job Harenberg

  29. Apixaban for Extended Treatment of Venous Thromboembolism

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, February 2013, New England Journal of Medicine (NEJM/MMS)

    Job Harenberg

  30. Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, February 2013, New England Journal of Medicine (NEJM/MMS)

    Job Harenberg, Prof.dr hab.n. med. Stanislaw Gluszek

  31. Clinical trials with new oral anticoagulants

    Article • January 2013, Schattauer GmbH

    Job Harenberg

  32. Concept of a point of care test to detect new oral anticoagulants in urine samples

    Article • Thrombosis Journal, January 2013, Springer Science + Business Media

    Job Harenberg

  33. Novel Methods for Assessing Oral Direct Factor Xa and Thrombin Inhibitors: Use of Point-of-Care Testing and Urine Samples

    Article • Seminars in Thrombosis and Hemostasis, December 2012, Thieme Publishing Group

    Job Harenberg

  34. Differences between indirect comparison studies of the oral anticoagulants for stroke prevention in atrial fibrillation: where do we go next?

    Article • QJM, December 2012, Oxford University Press (OUP)

    Job Harenberg

  35. Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery

    Article • September 2012, Schattauer GmbH

    Job Harenberg

  36. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban

    Article • July 2012, Wiley

    Job Harenberg

  37. A multi-center, prospective, open-label, 8-week study of certoparin for anticoagulation during maintenance hemodialysis – the membrane study

    Article • BMC Nephrology, June 2012, Springer Science + Business Media

    Job Harenberg, Peter Bramlage

  38. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial

    Article • The Lancet Neurology, June 2012, Elsevier

    Job Harenberg

  39. The C-terminal fragment of axon guidance molecule Slit3 binds heparin and neutralizes heparin's anticoagulant activity

    Article • Glycobiology, May 2012, Oxford University Press (OUP)

    Job Harenberg

  40. Discovery of PG545: A Highly Potent and Simultaneous Inhibitor of Angiogenesis, Tumor Growth, and Metastasis

    Article • Journal of Medicinal Chemistry, April 2012, American Chemical Society (ACS)

    Dr Vito Ferro, Job Harenberg

  41. Measurement of the new anticoagulants

    Article • Thrombosis Research, April 2012, Elsevier

    Job Harenberg

  42. Evaluation of the Prothrombin Time for Measuring Rivaroxaban Plasma Concentrations Using Calibrators and Controls

    Article • Clinical and Applied Thrombosis/Hemostasis, March 2012, SAGE Publications

    Job Harenberg

  43. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial

    Article • The Lancet Neurology, March 2012, Elsevier

    Job Harenberg

  44. Determination of Rivaroxaban in Human Plasma Samples

    Article • Seminars in Thrombosis and Hemostasis, February 2012, Thieme Publishing Group

    Job Harenberg

  45. Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, February 2012, New England Journal of Medicine (NEJM/MMS)

    Job Harenberg

  46. Determination of Dabigatran in Human Plasma Samples

    Article • Seminars in Thrombosis and Hemostasis, February 2012, Thieme Publishing Group

    Job Harenberg

  47. Determination of the anticoagulant effects of new oral anticoagulants: an unmet need

    Article • Expert Review of Hematology, February 2012, Taylor & Francis

    Job Harenberg

  48. Head-to-head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation: What’s next?

    Article • Thrombosis and Haemostasis, January 2012, Schattauer GmbH

    Job Harenberg

  49. New anticoagulants - promising and failed developments

    Article • December 2011, Wiley

    Job Harenberg

  50. Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, December 2011, New England Journal of Medicine (NEJM/MMS)

    Job Harenberg, MD Matteo Giorgi-Pierfranceschi

  51. Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban

    Article • Blood Coagulation & Fibrinolysis, December 2011, Wolters Kluwer Health

    Job Harenberg

  52. Apixaban versus Warfarin in Patients with Atrial Fibrillation

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, September 2011, New England Journal of Medicine (NEJM/MMS)

    Professor john j mcmurray, Job Harenberg

  53. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability

    Article • Journal of Thrombosis and Thrombolysis, August 2011, Springer Science + Business Media

    Job Harenberg

  54. Differences of Present Recommendations and Guidelines for Generic Low-Molecular-Weight Heparins: Is There Room for Harmonization

    Article • Clinical and Applied Thrombosis/Hemostasis, March 2011, SAGE Publications

    Job Harenberg

  55. Apixaban in Patients with Atrial Fibrillation

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, March 2011, New England Journal of Medicine (NEJM/MMS)

    Job Harenberg

  56. Overview on guidelines and recommendations for generic low-molecular-weight heparins

    Article • Thrombosis Research, February 2011, Elsevier

    Job Harenberg

  57. The prothrombin time/international normalized ratio (PT/INR) Line: derivation of local INR with commercial thromboplastins and coagulometers - two independent studies

    Article • January 2011, Wiley

    Job Harenberg

  58. Oral Rivaroxaban for Symptomatic Venous Thromboembolism

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, December 2010, New England Journal of Medicine (NEJM/MMS)

    Job Harenberg

  59. Antikoagulation im Alter

    Article • Der Internist, November 2010, Springer Science + Business Media

    Job Harenberg

  60. Future of Anticoagulant Therapy

    Article • July 2010, Wiley

    Job Harenberg

  61. Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced Mobility

    Article • Annals of Internal Medicine, July 2010, American College of Physicians

    Job Harenberg

  62. Synthesis and Biological Evaluation of Polysulfated Oligosaccharide Glycosides as Inhibitors of Angiogenesis and Tumor Growth

    Article • Journal of Medicinal Chemistry, February 2010, American Chemical Society (ACS)

    Dr Vito Ferro, Job Harenberg

  63. Interaction of heparin with cationic molecular probes: Probe charge is a major determinant of binding stoichiometry and affinity

    Article • Bioorganic & Medicinal Chemistry Letters, February 2010, Elsevier

    Job Harenberg

  64. A fluorescent probe for the quantification of heparin in clinical samples with minimal matrix interference

    Article • Chemical Communications, January 2010, Royal Society of Chemistry

    Job Harenberg

  65. Idraparinux and idrabiotaparinux

    Article • Expert Review of Clinical Pharmacology, January 2010, Taylor & Francis

    Job Harenberg

  66. Dabigatran versus Warfarin in Patients with Atrial Fibrillation

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, September 2009, New England Journal of Medicine (NEJM/MMS)

    Job Harenberg, Professor Antonis S Manolis

  67. New Anticoagulants in Atrial Fibrillation

    Article • Seminars in Thrombosis and Hemostasis, September 2009, Thieme Publishing Group

    Job Harenberg

  68. The expanded Global Registry of Acute Coronary Events: Baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes

    Article • American Heart Journal, August 2009, Elsevier

    Job Harenberg

  69. Thrombelastometer and low molecular weight heparin

    Article • Anaesthesia, August 2009, Wiley

    Job Harenberg

  70. Recommendations on biosimilar low-molecular-weight heparins

    Article • Journal of Thrombosis and Haemostasis, July 2009, Wiley

    Job Harenberg

  71. Neue Wirkstoffe zur Thromboembolieprophylaxe

    Article • Der Internist, April 2009, Springer Science + Business Media

    Job Harenberg

  72. LMWH – New mechanisms of action

    Article • Thrombosis Research, January 2009, Elsevier

    Job Harenberg

  73. Detection and neutralisation of heparin by a fluorescent ruthenium compound

    Article • Thrombosis and Haemostasis, January 2009, Schattauer GmbH

    Job Harenberg

  74. Development of idraparinux and idrabiotaparinux for anticoagulant therapy

    Article • Thrombosis and Haemostasis, January 2009, Schattauer GmbH

    Job Harenberg

  75. Heparin and its derivatives - Present and future

    Article • Thrombosis and Haemostasis, January 2009, Schattauer GmbH

    Job Harenberg

  76. Development of New Anticoagulants: Present and Future

    Article • Seminars in Thrombosis and Hemostasis, November 2008, Thieme Publishing Group

    Job Harenberg

  77. AFFECT: a prospective, open-label, multicenter trial to evaluate the feasibility and safety of a short-term treatment with subcutaneous certoparin in patients with persistent non-valvular atrial fibrillation

    Article • Clinical Research in Cardiology, March 2008, Springer Science + Business Media

    Job Harenberg

  78. Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials

    Article • February 2008, Wiley

    Job Harenberg

  79. Anticoagulant effects of Idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials

    Article • European Journal of Clinical Pharmacology, February 2008, Springer Science + Business Media

    Job Harenberg

  80. Current and Future Prospects for Anticoagulant Therapy: Inhibitors of Factor Xa and Factor IIa

    Article • Seminars in Thrombosis and Hemostasis, February 2008, Thieme Publishing Group

    Job Harenberg

  81. SASAT (South Asian Society on Atherosclerosis & Thrombosis) Proposal for Regulatory Guidelines for Generic Low-molecular Weight Heparins (LMWHs)

    Article • Clinical and Applied Thrombosis/Hemostasis, December 2007, SAGE Publications

    Job Harenberg

  82. Determination of Antithrombin-Dependent Factor Xa Inhibitors by Prothrombin-Induced Clotting Time

    Article • Seminars in Thrombosis and Hemostasis, July 2007, Thieme Publishing Group

    Job Harenberg

  83. Antiplatelet drug induced isolated profound thrombocytopenia in interventional cardiology: a review based on individual case reports

    Article • Journal of Thrombosis and Thrombolysis, January 2007, Springer Science + Business Media

    Job Harenberg

  84. Treatment of a woman with lupus and thromboembolism and cutaneous intolerance to heparins using fondaparinux during pregnancy

    Article • Thrombosis Research, January 2007, Elsevier

    Job Harenberg

  85. Observations of Alanine Aminotransferase and Aspartate Aminotransferase in THRIVE Studies Treated Orally with Ximelagatran

    Article • International Journal of Toxicology, May 2006, SAGE Publications

    Job Harenberg

  86. Old and new risk factors for upper extremity deep venous thrombosis - a rebuttal

    Article • Journal of Thrombosis and Haemostasis, April 2006, Wiley

    Job Harenberg

  87. Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran

    Article • European Journal of Clinical Pharmacology, January 2006, Springer Science + Business Media

    Job Harenberg

  88. Dysphagie nach Einnahme einer Paracetamoltablette unter oraler Antikoagulation

    Article • Der Internist, December 2005, Springer Science + Business Media

    Job Harenberg

  89. Prophylaxis of Thrombotic and Embolic Events in Acute Ischemic Stroke With the Low-Molecular-Weight Heparin Certoparin: Results of the PROTECT Trial

    Article • Stroke, November 2005, Wolters Kluwer Health

    Job Harenberg

  90. Impact of ABO blood groups on tirofiban mediated inhibition of platelet function

    Article • Platelets, November 2005, Taylor & Francis

    Job Harenberg

  91. Collaborative study on monitoring methods to determine direct thrombin inhibitors lepirudin and argatroban

    Article • Journal of Thrombosis and Haemostasis, September 2005, Wiley

    Job Harenberg

  92. Comparison of Two Different Ecarin Clotting Time Methods

    Article • Journal of Thrombosis and Thrombolysis, August 2005, Springer Science + Business Media

    Job Harenberg

  93. The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients: a rebuttal

    Article • Journal of Thrombosis and Haemostasis, July 2005, Wiley

    Job Harenberg

  94. Letter to the Editor

    Article • Lupus, May 2005, SAGE Publications

    Job Harenberg

  95. Treatment of Patients with a History of Heparin-Induced Thrombocytopenia and Anti-Lepirudin Antibodies with Argatroban

    Article • Journal of Thrombosis and Thrombolysis, February 2005, Springer Science + Business Media

    Job Harenberg

  96. Vorhofflimmern und Thromboembolieprophylaxe bei �lteren Patienten

    Article • Zeitschrift für Kardiologie, February 2005, Springer Science + Business Media

    Job Harenberg

  97. Effects of vitamin K antagonist phenprocoumon on activated partial thromboplastin time measurement of direct thrombin inhibitors

    Article • Blood Coagulation & Fibrinolysis, October 2004, Wolters Kluwer Health

    Job Harenberg

  98. Prevention and treatment of deep vein thrombosis with ximelagatran

    Article • DMW - Deutsche Medizinische Wochenschrift, July 2004, Thieme Publishing Group

    Job Harenberg

  99. Treatment of patients initially for acute deep vein thrombosis with a low-molecular-weight heparin at a fixed, body weight-independent dosage

    Article • Journal of Thrombosis and Haemostasis, June 2004, Wiley

    Job Harenberg

  100. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? Yes

    Article • Journal of Thrombosis and Haemostasis, April 2004, Wiley

    Job Harenberg

  101. Thrombosetherapie mit niedermolekularem Heparin

    Article • Medizinische Klinik, September 2003, Springer Science + Business Media

    Job Harenberg

  102. Effects of lepirudin, argatroban and melagatran and additional influence of phenprocoumon on ecarin clotting time

    Article • Thrombosis Research, January 2003, Elsevier

    Job Harenberg

  103. Anticoagulant-related skin reactions

    Article • Expert Opinion on Drug Safety, September 2002, Informa Healthcare

    Job Harenberg

  104. Fixed-dose versus adjusted-dose low molecular weight heparin for the initial treatment of patients with deep venous thrombosis

    Article • Current Opinion in Pulmonary Medicine, September 2002, Wolters Kluwer Health

    Job Harenberg

  105. Empfehlungen zur Thromboembolieprophylaxe bei internistischen Patienten im Alter

    Article • July 2002, Springer Science + Business Media

    Job Harenberg

  106. Bioequivalence of subcutaneous and intravenous body-weight-independent high-dose low-molecular-weight heparin Certoparin on anti-Xa, Heptest, and tissue factor pathway inhibitor activity in volunteers

    Article • Blood Coagulation & Fibrinolysis, June 2002, Wolters Kluwer Health

    Job Harenberg

  107. Development of a High-Pressure Liquid Chromatography Method for Diagnosis of Heparin-Induced Thrombocytopenia

    Article • American Journal of Clinical Pathology, June 2002, Oxford University Press (OUP)

    Job Harenberg

  108. Development of an HPLC Method for the Diagnosis of Heparin-Induced Thrombocytopenia

    Article • AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie, April 2002, Thieme Publishing Group

    Job Harenberg

  109. Management of HIT II Patients with Hirudin Antibodies after Primary Therapy

    Article • AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie, April 2002, Thieme Publishing Group

    Job Harenberg

  110. Article • January 2002, Springer Science + Business Media

    Job Harenberg

  111. Comparative Antithrombotic Potencies of Direct Thrombin Inhibitors and Low-Molecular-Weight Heparins in an Ex Vivo Human Experimental Thrombosis Model

    Article • Seminars in Thrombosis and Hemostasis, January 2002, Thieme Publishing Group

    Job Harenberg

  112. Low-Molecular-Weight Heparin and Dermatan Sulfate End Group-Labeled with Tyramine and Fluorescein. Biochemical and Biological Characterization of the Fluorescent-Labeled Heparin Derivative

    Article • Seminars in Thrombosis and Hemostasis, January 2002, Thieme Publishing Group

    Job Harenberg

  113. Monitoring of Anticoagulant Effects of Direct Thrombin Inhibitors

    Article • Seminars in Thrombosis and Hemostasis, January 2002, Thieme Publishing Group

    Job Harenberg

  114. Effect of Phenprocoumon on Monitoring of Lepirudin, Argatroban, Melagatran and Unfractionated Heparin with the PiCT Method

    Article • Pathophysiology of Haemostasis and Thrombosis, January 2002, Karger Publishers

    Job Harenberg

  115. Emerging concepts in thromboprophylaxis

    Article • Pathophysiology of Haemostasis and Thrombosis, January 2002, Karger Publishers

    Job Harenberg

  116. Heparin-induced thrombocytopenia: Pathophysiology and new treatment options

    Article • Pathophysiology of Haemostasis and Thrombosis, January 2002, Karger Publishers

    Job Harenberg

  117. Laboratory diagnosis of heparin-induced thrombocytopenia type II after clearance of platelet factor 4/heparin complex

    Article • Journal of Laboratory and Clinical Medicine, June 2001, Elsevier

    Job Harenberg

  118. Effect of Thrombin Inhibitors and a Glycoprotein IIb/IIIa Receptor Antagonist in an Ex Vivo Human Experimental Thrombosis Model

    Article • Seminars in Thrombosis and Hemostasis, January 2001, Thieme Publishing Group

    Job Harenberg

  119. Effects of a Heparin-Binding Protein on Blood Coagulation and Platelet Function

    Article • Seminars in Thrombosis and Hemostasis, January 2001, Thieme Publishing Group

    Job Harenberg

  120. Reduction in Thrombus Extension and Clinical End Points in Patients after Initial Treatment for Deep Vein Thrombosis with the Fixed-Dose Body Weight-Independent Low Molecular Weight Heparin Certoparin

    Article • Seminars in Thrombosis and Hemostasis, January 2001, Thieme Publishing Group

    Job Harenberg

  121. Cutaneous Reactions to Anticoagulants

    Article • January 2001, Springer Science + Business Media

    Job Harenberg

  122. A New Therapeutic Option by Subcutaneous Recombinant Hirudin in Patients with Heparin-induced Thrombocytopenia Type II

    Article • Thrombosis Research, August 2000, Elsevier

    Job Harenberg

  123. Quantitative Determination of PEG-Hirudin in Human Plasma Using a Competitive Enzyme-Linked Immunosorbent Assay

    Article • Thrombosis Research, July 2000, Elsevier

    Job Harenberg

  124. Risk assessment of venous thromboembolism in medical patients

    Article • Seminars in Hematology, July 2000, Elsevier

    Job Harenberg

  125. Re-exposure to recombinant (r)-hirudin in antihirudin antibody-positive patients with a history of heparin-induced thrombocytopenia

    Article • British Journal of Haematology, May 2000, Wiley

    Job Harenberg

  126. Determination of serotonin release from platelets by enzyme immunoassay in the diagnosis of heparin-induced thrombocytopenia

    Article • British Journal of Haematology, April 2000, Wiley

    Job Harenberg

  127. Treatment of an acute flush reaction caused by subcutaneous r-hirudin with pegylated hirudin

    Article • British Journal of Haematology, March 2000, Wiley

    Job Harenberg

  128. Management of Heparin-Associated Thrombocytopenia in Pregnancy with Subcutaneous r-Hirudin

    Article • Gynecologic and Obstetric Investigation, January 2000, Karger Publishers

    Job Harenberg

  129. Generation of Anti-Hirudin Antibodies in Heparin-Induced Thrombocytopenic Patients Treated With R-Hirudin

    Article • Circulation, October 1999, Wolters Kluwer Health

    Job Harenberg

  130. Reduction of Platelet Activity Markers in Type II Hypercholesterolemic Patients by a HMG-CoA-Reductase Inhibitor

    Article • Thrombosis Research, September 1999, Elsevier

    Job Harenberg

  131. Antithrombotische Therapie

    Article • Der Internist, August 1999, Springer Science + Business Media

    Job Harenberg

  132. Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment

    Article • British Journal of Haematology, July 1999, Wiley

    Job Harenberg

  133. Association of heparin-induced skin lesions, intracutaneous tests, and heparin-induced IgG

    Article • Allergy, May 1999, Wiley

    Job Harenberg

  134. Determination of heparin-induced IgG antibody in heparin-induced thrombocytopenia type II

    Article • European Journal of Clinical Investigation, March 1999, Wiley

    Job Harenberg

  135. Determination of heparin-induced IgG antibody by fluorescence-linked immunofiltration assay (FLIFA)

    Article • Journal of Immunological Methods, January 1999, Elsevier

    Job Harenberg

  136. Review of pharmacodynamics, pharmacokinetics, and therapeutic properites of sulodexide

    Article • Medicinal Research Reviews, January 1998, Wiley

    Job Harenberg

  137. Niedermolekulare Heparine

    Article • Der Hautarzt, November 1997, Springer Science + Business Media

    Job Harenberg

  138. Chromatographic and electrophoretic applications for the analysis of heparin and dermatan sulfate

    Article • Journal of Chromatography B Biomedical Sciences and Applications, October 1996, Elsevier

    Job Harenberg

  139. Purification of the monoclonal heparin antibody H-1.18

    Article • Journal of Chromatography A, September 1996, Elsevier

    Job Harenberg

  140. Purity of glycosaminoglycan-related compounds using capillary electrophoresis

    Article • Electrophoresis, January 1996, Wiley

    Job Harenberg

  141. Analysis of heparin binding to human leukocytes using a fluorescein-5-isothiocyanate labeled heparin fragment

    Article • Cytometry Part A, January 1996, Wiley

    Job Harenberg

  142. N' alkylamine low molecular mass heparins (LMM-heparin-tyramine and LMM-heparin-tyramine-fitc) exhibit long lasting anticoagulant effects

    Article • Thrombosis Research, November 1995, Elsevier

    Job Harenberg

  143. Magnetic bead protamine-linked microtiter assay for detection of heparin using iodinated low-molecular-mass heparin-tyramine

    Article • Thrombosis Research, July 1995, Elsevier

    Job Harenberg

  144. The injection of heparin prolongs the plasma clearance of oxidized low density lipoprotein in the rat

    Article • Thrombosis Research, April 1995, Elsevier

    Job Harenberg

  145. Tissue factor pathway inhibitor in infants and children

    Article • Thrombosis Research, March 1994, Elsevier

    Job Harenberg

  146. Synthesis of a N′-Alkylamine Anticoagulant Active Low-Molecular-Mass Heparin for Radioactive and Fluorescent Labeling

    Article • March 1994, Elsevier

    Job Harenberg

  147. Hepatic uptake of a modified low molecular weight heparin in rats.

    Article • November 1992, American Society for Clinical Investigation

    Job Harenberg

  148. Heparin study in internal medicine (HESIM): design and preliminary results

    Article • Thrombosis Research, October 1992, Elsevier

    Job Harenberg

  149. Anti-Xa clotting activities in different hepatic-triglyceride lipase preparations from post-heparin plasma

    Article • Thrombosis Research, September 1991, Elsevier

    Job Harenberg

  150. Partial in vivo neutralisation of plasma anticoagulant effects of lomoparanR (Org 10172) by protamine chloride

    Article • Thrombosis Research, July 1991, Elsevier

    Job Harenberg

  151. Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients

    Article • Thrombosis Research, August 1990, Elsevier

    Job Harenberg

  152. Effect of dried garlic on blood coagulation, fibrinolysis, platelet aggregation and serum cholesterol levels in patients with hyperlipoproteinemia

    Article • Atherosclerosis, December 1988, Elsevier

    Job Harenberg

  153. Pharmacology and special clinical applications of low-molecular-weight heparins

    Article • American Journal of Hematology, December 1988, Wiley

    Job Harenberg

  154. Bioavailability and antagonization of the low molecular weight heparin CY 216 in man

    Article • Thrombosis Research, November 1986, Elsevier

    Job Harenberg

  155. Phenprocoumon metabolites in human plasma; characterization by HPLC and GC-MS

    Article • European Journal of Clinical Pharmacology, September 1986, Springer Science + Business Media

    Job Harenberg

  156. Lipolytic activities of low molecular weight heparins

    Article • Thrombosis Research, June 1986, Elsevier

    Job Harenberg

  157. Anticoagulant and lipolytic effects of a low molecular weight heparin fraction

    Article • Thrombosis Research, September 1985, Elsevier

    Job Harenberg

  158. Inhibition of low molecular weight heparin by protamine chloride in vivo

    Article • Thrombosis Research, April 1985, Elsevier

    Job Harenberg

  159. INTRAVENOUS IgG FOR PATIENTS WITH SPONTANEOUS INHIBITOR TO FACTOR VIII

    Article • February 1985, Elsevier

    Job Harenberg

  160. Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment

    Article • European Journal of Clinical Pharmacology, January 1985, Springer Science + Business Media

    Job Harenberg

  161. Effect of single and multiple doses of sulphinpyrazone on antipyrine metabolism and urinary excretion of 6-beta-hydroxycortisol

    Article • European Journal of Clinical Pharmacology, November 1983, Springer Science + Business Media

    Job Harenberg

  162. Disposition of human fibrinopeptide A in normal and nephrectomized rabbits

    Article • Thrombosis Research, October 1983, Elsevier

    Job Harenberg

  163. TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS BY NEW HEPARINOID

    Article • April 1983, Elsevier

    Job Harenberg

  164. Plasma hypercoagulability after termination of oral anticoagulants

    Article • Thrombosis Research, March 1983, Elsevier

    Job Harenberg

  165. Cimetidine does not increase the anticoagulant effect of phenprocoumon.

    Article • August 1982, Wiley

    Job Harenberg

  166. Lack of effect of cimetidine on action of phenprocoumon

    Article • European Journal of Clinical Pharmacology, July 1982, Springer Science + Business Media

    Job Harenberg

  167. Blood coagulation changes during effective thrombolysis using urokinase and heparin

    Article • Thrombosis Research, January 1982, Elsevier

    Job Harenberg

  168. Fibrinopeptide A (FPA) radioimmunoassay influence of the affinity of the second antibody for FPA antiserum

    Article • Thrombosis Research, February 1981, Elsevier

    Job Harenberg

  169. FIBRINOPEPTIDE A IN ACUTE CORONARY INSUFFICIENCY

    Article • January 1981, Elsevier

    Job Harenberg

  170. Acute cardiovascular reactions after cigarette smoking

    Article • Atherosclerosis, January 1980, Elsevier

    Job Harenberg

  171. Evaluation of smoking-induced effects on sympathetic, hemodynamic and metabolic variables with respect to plasma nicotine and COHb levels

    Article • Atherosclerosis, July 1979, Elsevier

    Job Harenberg

  172. Fibrinopeptide a in human plasma - evaluation of a new radioimmunoassay technique on microliter - plates

    Article • Thrombosis Research, January 1979, Elsevier

    Job Harenberg